" class="no-js "lang="en-US"> Neurovation Labs - Medtech Alert
Monday, September 15, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Neurovation Labs | Pharmtech Focus

Neurovation Labs

About Neurovation Labs

Neurovation Labs

Neurovation Labs is a biotechnology company revolutionizing the way mental health disorders are diagnosed and treated, focusing on PTSD and other brain traumas. Founded in 2016, the company is leveraging a major brain biomarker discovery to develop two products for PTSD: (1) a molecular diagnostic and (2) a companion targeted treatment. Both products are in preclinical development and have the potential to transform brain trauma healthcare.

Related Story

Diseases

 Neurovation Labs Awarded Additional Air Force Phase II Contract Worth $1.25M to Develop Tools to Mitigate PTSD and Other Brain Traumas | Pharmtech Focus

Neurovation Labs Awarded Additional Air Force Phase II Contract Worth $1.25M to Develop Tools to Mitigate PTSD and Other Brain Traumas

June 22 2022

Neurovation Labs, Inc., a biotechnology company developing the first objective diagnostic and companion treatment for […]